NCT03599765: Systemic Therapy With or Without Local Consolidative Therapy in Treating Participants With Oligometastatic Solid Tumor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 4 prior lines of systemic therapy administered to treat metastatic disease; Patients with diffuse metastatic processes including leptomeningeal disease; Patients with metastatic effusion (e.g. pleural effusion or ascites)

Comments are closed.

Up ↑